Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects

Biomed Chromatogr. 2012 Mar;26(3):314-26. doi: 10.1002/bmc.1660. Epub 2011 Jun 8.

Abstract

A sensitive, selective and rapid liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous determination of bupropion (BUP) and its major active metabolite hydroxybupropion (HBUP) in human plasma. Separation of both the analytes and venlafaxine as internal standard (IS) from 50 μL human plasma was carried out by solid-phase extraction. The chromatographic separation of the analytes was achieved on a Zorbax Eclipse XDB C(18) (150 × 4.6 mm, 5 µm) analytical column using isocratic mobile phase consisting of 20 mm ammonium acetate-methanol (10:90, v/v), with a resolution factor of 3.5. The method was validated over a wide dynamic concentration range of 0.1-350 ng/mL for BUP and 0.1-600 ng/mL for HBUP. The matrix effect was assessed by post-column infusion and the mean process efficiency was 96.08 and 94.40% for BUP and HBUP, respectively. The method was successfully applied to a bioequivalence study of 150 mg BUP (test and reference) extended release tablet formulation in 12 healthy Indian male subjects under fed conditions.

Publication types

  • Validation Study

MeSH terms

  • Antidepressive Agents, Second-Generation / blood*
  • Antidepressive Agents, Second-Generation / pharmacokinetics
  • Bupropion / analogs & derivatives*
  • Bupropion / blood*
  • Bupropion / pharmacokinetics
  • Chromatography, Liquid / methods*
  • Humans
  • India
  • Limit of Detection
  • Quality Control
  • Reference Standards
  • Reference Values
  • Tandem Mass Spectrometry / methods*
  • Therapeutic Equivalency

Substances

  • Antidepressive Agents, Second-Generation
  • Bupropion
  • radafaxine